Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APC201 for pain associated with knee osteoarthritis
ACTRN12623000273684Phase 2Completed
- Sponsor
- Andros Pharmaceuticals Co., Ltd.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of diclofenac in knee osteoarthritis (OA) (3 arms), sponsored by Andros Pharmaceuticals Co., Ltd. Primary endpoint: Change from baseline in WOMAC LK3.1 pain subscale score in the target knee. Started Feb 2024; status: completed.
02
Drugs
diclofenac
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12623000273684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000273684.